Recent

% | $
Quotes you view appear here for quick access.

SAVİENT PHARM AŞ Message Board

nancy_physical 13 posts  |  Last Activity: Apr 25, 2016 4:59 PM Member since: Nov 20, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Wish me luck hope SKLN still keep o.21 price, tomorrow morning I have money to buy 100K shares

    Sentiment: Strong Buy

  • nancy_physical by nancy_physical Apr 20, 2016 2:24 PM Flag

    Wow this HTBX going to hit %500

    At the American Conference for Cancer Research (AACR) Annual Meeting, immuno-oncology company Heat Biologics, Inc. (NASDAQ:HTBX) has presented the preclinical results from its team-up with DNA-based intratumoral cancer immunotherapy company OncoSec Medical, Inc. (NASDAQ:ONCS), which evaluated immunotherapy platform integrations of the company’s products.
    The presentation entitled, “In vivo intra-tumoral electroporation of Gp96-Ig/Fc-OX40L stimulates CD8+ T cell cross-priming to tumor specific neoantigens” was delivered on April 17. Similarly, Heat Biologics also presented other abstracts at the AACR. The “Vesigenurtacel-L stimulates tumor infiltration of unique polyclonal T cell clones in non-muscle invasive bladder cancer patients” and the “Combination immunotherapy: T cell costimulation (OX40L, TL1A, 4-1BBL and ICOSL) secreted locally by Gp96-Ig vaccines, elicits robust antigen-specific, memory T cell responses and tumor elimination” presentations were delivered on April 18.
    Preclinical Conclusions
    The researchers have found out that integrating the ComPACT vaccine of Heat Biologics and the intratumoral DNA electroporation delivery platform of OncoSec Medical stimulates an expansion of the neoantigen-specific CD8+ cells. This results to the regression of both treated and untreated cancer lesions (colorectal and melanoma cancer).
    Taylor Schreiber, M.D., Ph.D., Heat Biologics Chief Scientific Officer, explained that the preclinical study showed a robust neoantigen T cell response and tumor regressions. This indicates that a systemic anti-tumor response can reflect what is seen in metastatic lesions. Moreover, Schreiber added that the results of the studies and the initiative itself are promising, as the combination does not come with complexities involving personalized therapies.
    Heat Biologics, OncoSec Medical Tie-Up
    Robert H. Pierce, M.D., OncoSec Medical Chief Scientific Officer, expressed that both companies are even more driven

    Sentiment: Strong Buy

  • nancy_physical by nancy_physical Apr 15, 2016 9:50 AM Flag

    Will buy out by JnJ for HTBX Targeting an $11 Billion Market, check head line news today

    Sentiment: Strong Buy

  • nancy_physical by nancy_physical Apr 15, 2016 9:44 AM Flag

    HTBX Targeting an $11 Billion Market, Heat Biologics' Cancer Vaccines Provide Investors a Huge Opportunity

    Sentiment: Strong Buy

  • htbx head line news for HTBX bladder cancer

    Sentiment: Strong Buy

  • nancy_physical by nancy_physical Apr 15, 2016 9:35 AM Flag

    All in This 2 HTBX + SKLN on big fry today see u guys at $1 or $1.5

    Skyline Medical Inc

    (NASDAQ:SKLN)

    Heat Biologics Inc

    (NASDAQ:HTBX)
    Check head line news for HTBX bladder cancer
    Targeting an $11 Billion Market, Heat Biologics' Cancer Vaccines Provide Investors a Huge Opportunity

    Sentiment: Strong Buy

  • HTBX going to yahoo top list tomorrow

    Sentiment: Strong Buy

  • Tomorrow top gain list will see this HTBX If their CEO good business and good talk will be like next of CPXX and AQXP, but so far sound like it, offer cheap stock to MM's Cut cost...... I like HTBX

    Sentiment: Strong Buy

    Sentiment: Strong Buy

  • Reply to

    HTBX is next of CPXX and AQXP. Up %500 to %1000

    by strongbuy33 Apr 14, 2016 12:14 PM
    nancy_physical nancy_physical Apr 14, 2016 2:30 PM Flag

    If their CEO good business and good talk will be like next of CPXX and AQXP, but so far sound like it, offer cheap stock to MM's Cut cost...... I like HTBX

    Sentiment: Strong Buy

  • Heat Biologics, Inc is good company, dec-31 2 P3 fda approve

    Sentiment: Strong Buy

  • nancy_physical by nancy_physical Mar 18, 2016 11:18 PM Flag

    HRTX 2 drugs approve on EOY

    Heron Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Progress


    REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 6, 2015-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today reported third quarter 2015 financial results and highlighted recent corporate progress.

    Recent Corporate Progress:
    • In October 2015, Heron appointed Neil J. Clendeninn, M.D., Ph.D. as Senior Vice President and Chief Medical Officer. Dr. Clendeninn brings more than 25 years of drug development and clinical practice experience to his role at Heron. Prior to his appointment, Dr. Clendeninn advised Heron during the recently completed MAGIC study for SUSTOL® (granisetron) Injection, extended release and with the resubmission of Heron’s New Drug Application (NDA) for SUSTOL to the U.S. Food and Drug Administration (FDA). Dr. Clendeninn, in addition to his experience as a practicing physician, has held academic positions, and served as a board member and scientific advisor for numerous institutions and companies within the oncology field.
    • In September 2015, Heron reported positive, top-line results from its recently completed Phase 2 clinical study of HTX-011 in the management of post-operative pain in patients undergoing bunionectomy. In the study, HTX-011 showed a significant reduction in pain intensity, reduction in the need for opioid rescue medications, and increase in time to first use of rescue medications.
    • In September 2015, the FDA accepted for review Heron’s NDA resubmission for SUSTOL for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) regimens. The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of January 17, 2016.

    Phase 2 Topline Data Expected in the Fo

    Sentiment: Strong Buy

  • Another cheap share offer coming on Monday, 0.60

    Sentiment: Strong Sell

  • nancy_physical nancy_physical Mar 9, 2016 2:01 PM Flag

    I don't understand either, PPHMP up a lot, same company.

    Sentiment: Hold